Novartis (NYSE:NVS) unit Advanced Accelerator Applications S.A. (AAA) inks an exclusive option and license agreement with FUJIFILM Toyama Chemical for global development and commercialization rights (ex-Japan) to FF-10158 for oncology indications.
FF-10158 is small molecule antagonist with high affinity for certain receptors on the surface of cancer cells. AAA plans to develop a "theragnostic" pairing of compounds, including a gallium 68-labeled drug for diagnosis and a lutetium 177-labeled drug for therapeutic use.
Financial terms are not disclosed.
Subscribe for full text news in your inbox